Buprenorphine is a potential treatment for newborns with neonatal opioid withdrawal syndrome (NOWS). This workshop brings together experts in maternal-fetal medicine, maternal treatment of opioid use disorder, and neonatal outcomes. The attendees will discuss both scientific and practical opportunities and issues conducting trials regarding the use of buprenorphine in newborns with NOWS and other pediatric conditions requiring opioid therapy.
This meeting is part of the Helping to End Addiction Long-term Initiative, or National Institutes of Health HEAL (Helping to End Addiction Long-term) Initiative, research efforts to enhance outcomes for infants and children exposed to opioids.
* Review the state of the science, knowledge gaps, and practical considerations regarding use of buprenorphine in infants for treatment of neonatal opioid withdrawal syndrome (NOWS)
* Propose next steps to test the safety and efficacy of buprenorphine for treating NOWS